bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Vasectomy and Risk of Prostate Cancer in a Screening Trial
Authors: Shoag Jonathan , Savenkov Oleksander , Christos Paul J. , Mittal Sameer , Halpern Joshua A. , Askin Gulce , Shoag Daniel , Golan Ron , Lee Daniel J. , O'Malley Padraic , Najari Bobby , Eisner Brian , Hu Jim C. , Scherr Douglas , Schlegel Peter , Barbieri Christopher E.
Published: April 2023

Abstract
Background: Vasectomy has been implicated as a risk factor for prostate cancer in multiple epidemiologic studies over the past 25 years. Whether this relationship is causal remains unclear. This study examines the association between vasectomy and prostate cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, which randomized men to usual care or annual prostate cancer screening.

Methods: We performed a retrospective analysis of 13-year screening and outcomes data from the PLCO trial. Multivariable Cox proportional hazards regression stratified by study arm and age at vasectomy was performed.

Results: There was an increased risk of prostate cancer in men who had undergone a vasectomy and were randomized to the usual care arm of the study (adjusted HR, 1.11; 95% confidence interval, 1.03–1.20; P = 0.008). There was no association between vasectomy and diagnosis of prostate cancer in men randomized to the prostate cancer screening arm. Only men undergoing vasectomy at an older age in the usual care arm of the study, but not the prostate cancer screening arm, were at increased risk of being diagnosed with prostate cancer.

Conclusions: Vasectomy was not associated with prostate cancer risk among men who were screened for prostate cancer as part of a clinical trial, but was associated with prostate cancer detection in men receiving usual care.

Impact: The positive association between vasectomy and prostate cancer is likely related to increased detection of prostate cancer based on patterns of care rather than a biological effect of vasectomy on prostate cancer development. Cancer Epidemiol Biomarkers Prev; 26(11); 1653–9. ©2017 AACR.
Data from Integrated Analysis of Multiple Gene Expression Profiling Datasets Revealed Novel Gene Signatures and Molecular Markers in Nasopharyngeal Carcinoma
Authors: Huang Chen , Tang Hailin , Zhang Wenling , She Xiaoling , Liao Qianjin , Li Xiaoling , Wu Minghua , Li Guiyuan
Published: April 2023

Abstract
Purpose: To identify the novel gene signatures and molecular markers of nasopharyngeal carcinoma (NPC) by integrated bioinformatics analysis of multiple gene expression profiling datasets.

Experimental Design: Seven published gene expression profiling studies and one of our unpublished works were reanalyzed to identify the common significantly dysregulated (CSD) genes in NPC. Overrepresentation analysis of cytogenetic bands, Gene Ontology (GO) categories, pathways were used to explore CSD genes functionally associated with carcinogenesis. The protein expressions of selected CSD genes were examined by immunohistochemistry on tissue microarrays, and the correlations of their expressions with clinical outcomes were evaluated.

Results: Using the criteria (genes reported deregulated in more than one study), a total of 962 genes were identified as the CSD genes in NPC. Four upregulated (BUB1B, CCND2, CENPF, and MAD2L1) and two downregulated (LTF and SLPI) genes were markedly reported in six studies. The enrichments of chromosome aberrations were 2q23, 2q31, 7p15, 12q15, 12q22, 18q11, and 18q12 in upregulated genes and 14q32 and 16q13 in downregulated genes. The activated GO categories and pathways related to proliferation, adhesion, invasion, and downregulated immune response had been functionally associated with NPC. SLPI significantly downregulated in nasopharyngeal adenocarcinoma. Furthermore, the high expression of BUB1B or CENPF was associated with poor overall survival of patients.

Conclusion: It was first clearly identified the dysregulated expression of BUB1B and SLPI in NPC tissues.

Impact: Further studies of the CSD genes as gene signatures and molecular markers of NPC might improve the understanding of the disease and identify new therapeutic targets. Cancer Epidemiol Biomarkers Prev; 21(1); 166–75. ©2011 AACR.
Data from SOX2 Autoantibodies As Noninvasive Serum Biomarker for Breast Carcinoma
Authors: Sun Yu , Zhang Rui , Wang Minjie , Zhang Yuan , Qi Jun , Li Jinming
Published: April 2023

Abstract
Background: A clear association has been established between antibodies to the transcription factor sex-determining region Y (SRY)-box 2 (SOX2) and small cell lung cancer. In light of the pathologic role of SOX2 and its aberrant expression in breast cancer, we measured serum SOX2 autoantibodies (SOX2-Abs) in breast cancer patients.

Methods: The presence of SOX2-Abs was determined by an indirect enzyme-linked immunosorbent assay (ELISA) in sera from 282 patients with breast cancer, 78 patients with benign breast disease, and 194 healthy women.

Results: SOX2-Abs were more prevalent in patients with breast cancer (18.4%) compared with healthy women (2.6%, P < 0.0001), and patients with benign breast disease (6.4%, P = 0.011). The concentrations of circulating SOX2-Abs were found to discriminate between breast cancer patients and healthy controls (P < 0.001) and between breast cancer patients and those with benign breast disease (P < 0.001). In addition, measurement of SOX2-Abs was more effective than assays of serum tissue polypeptide-specific antigen, carcinoembryonic antigen, carbohydrate antigen (CA) 125, and CA 15-3 in distinguishing between malignant and benign breast disease. In breast cancer patients, the prevalence of SOX2-Abs was associated with a higher tumor grade (P = 0.021) and positive nodal status (P = 0.021).

Conclusion: The presence of SOX2-Abs in breast cancer may be of clinical value.

Impact: This study provides the first evidence for the presence of circulating SOX2-Abs in breast cancer and shows their potential clinical application. Cancer Epidemiol Biomarkers Prev; 21(11); 2043–7. ©2012 AACR.
Data from Insurance Status and Racial Disparities in Cancer-Specific Mortality in the United States: A Population-Based Analysis
Authors: Pan Hubert Y. , Walker Gary V. , Grant Stephen R. , Allen Pamela K. , Jiang Jing , Guadagnolo B. Ashleigh , Smith Benjamin D. , Koshy Matthew , Rusthoven Chad G. , Mahmood Usama
Published: April 2023

Abstract
Background: Cancer-specific mortality (CSM) is known to be higher among blacks and lower among Hispanics compared with whites. Private insurance confers CSM benefit, but few studies have examined the relationship between insurance status and racial disparities. We sought to determine differences in CSM between races within insurance subgroups.

Methods: A population-based cohort of 577,716 patients age 18 to 64 years diagnosed with one of the 10 solid malignancies causing the greatest mortality over 2007 to 2012 were obtained from Surveillance, Epidemiology, and End Results. A Cox proportional hazards model for CSM was constructed to adjust for known prognostic factors, and interaction analysis between race and insurance was performed to generate stratum-specific HRs.

Results: Blacks had similar CSM to whites among the uninsured [HR = 1.01; 95% confidence interval (CI), 0.96–1.05], but higher CSM among the Medicaid (HR = 1.04; 95% CI, 0.01–1.07) and non-Medicaid (HR = 1.14; 95% CI, 1.12–1.16) strata. Hispanics had lower CSM compared with whites among uninsured (HR = 0.80; 95% CI, 0.76–0.85) and Medicaid (HR = 0.88; 95% CI, 0.85–0.91) patients, but there was no difference among non-Medicaid patients (HR = 0.99; 95% CI, 0.97–1.01). Asians had lower CSM compared with whites among all insurance types: uninsured (HR = 0.80; 95% CI, 0.76–0.85), Medicaid (HR = 0.81; 95% CI, 0.77–0.85), and non-Medicaid (HR = 0.85; 95% CI, 0.83–0.87).

Conclusions: The disparity between blacks and whites was largest, and the advantage of Hispanic race was absent within the non-Medicaid subgroup.

Impact: These findings suggest that whites derive greater benefit from private insurance than blacks and Hispanics. Further research is necessary to determine why this differential exists and how disparities can be improved. Cancer Epidemiol Biomarkers Prev; 26(6); 869–75. ©2017 AACR.
Data from Spatial Analysis of Regional Factors and Lung Cancer Mortality in China, 1973–2013
Authors: Shen Xiaoping , Wang Limin , Zhu Li
Published: April 2023

Abstract
Background: China's lung cancer crude death rate has increased 6.9-fold from 1973 to 2014. During this time, the country experienced extremely rapid economic growth and social change. It is important to understand the effects of risk factors on lung cancer mortality (LCM) for better allocation of limited resources of cancer prevention and control in China.

Methods: Using three nationwide mortality surveys from 1973 to 2005, Global Health Data Exchange data in 2013, three nationwide smoking surveys from 1984 to 2013, four population censuses from 1964 to 2000, and other datasets, we have compiled datasets and developed spatial random effect models to assess the association of various area-level–contributing factors on LCM. Spatial scan statistics are used to detect high-risk clusters of LCM.

Results: LCM is higher in urban and more industrialized areas (RR = 1.17) compared with those in rural areas. The level of industrial development's effect is higher for men, which accounts for about 70% of all LCM. Smoking is positively associated with regional variation of LCM rates, and the effect is higher for women than for men.

Conclusions: The geographic pattern of high LCM in China is different from that of Western countries. LCM is positively associated with higher socioeconomic status, with more urbanized areas at a higher level of industrial development.

Impact: There is a need to further explore additional risk in the high-risk clusters. The study is about China, but this situation may happen in other countries experiencing rapid industrialization and other developing countries. Cancer Epidemiol Biomarkers Prev; 26(4); 569–77. ©2017 AACR.

See all the articles in this CEBP Focus section, “Geospatial Approaches to Cancer Control and Population Sciences.”
Data from Evaluation of Metabolite Biomarkers for Hepatocellular Carcinoma through Stratified Analysis by Gender, Race, and Alcoholic Cirrhosis
Authors: Xiao Junfeng , Zhao Yi , Varghese Rency S. , Zhou Bin , Di Poto Cristina , Zhang Lihua , Tadesse Mahlet G. , Ziada Dina Hazem , Shetty Kirti , Ressom Habtom W.
Published: April 2023

Abstract
Background: The effects of hepatocellular carcinoma on liver metabolism and circulating metabolites have been subjected to continuing investigation. This study compares the levels of selected metabolites in sera of hepatocellular carcinoma cases versus patients with liver cirrhosis and evaluates the influence of gender, race, and alcoholic cirrhosis on the performance of the metabolites as candidate biomarkers for hepatocellular carcinoma.

Methods: Targeted quantitation of 15 metabolites is performed by selected research monitoring in sera from 89 Egyptian subjects (40 hepatocellular carcinoma cases and 49 cirrhotic controls) and 110 U.S. subjects (56 hepatocellular carcinoma cases and 54 cirrhotic controls). Logistic regression models are used to evaluate the ability of these metabolites in distinguishing hepatocellular carcinoma cases from cirrhotic controls. The influences of gender, race, and alcoholic cirrhosis on the performance of the metabolites are analyzed by stratified logistic regression.

Results: Two metabolites are selected on the basis of their significance to both cohorts. Although both metabolites discriminate hepatocellular carcinoma cases from cirrhotic controls in males and Caucasians, they are insignificant in females and African Americans. One metabolite is significant in patients with alcoholic cirrhosis and the other in nonalcoholic cirrhosis.

Conclusions: The study demonstrates the potential of two metabolites as candidate biomarkers for hepatocellular carcinoma by combining them with α-fetoprotein (AFP) and gender. Stratified statistical analyses reveal that gender, race, and alcoholic cirrhosis affect the relative levels of small molecules in serum.

Impact: The findings of this study contribute to a better understanding of the influence of gender, race, and alcoholic cirrhosis in investigating small molecules as biomarkers for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev; 23(1); 64–72. ©2013 AACR.
Data from Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)
Authors: Lindström Sara , Schumacher Fredrick R. , Cox David , Travis Ruth C. , Albanes Demetrius , Allen Naomi E. , Andriole Gerald , Berndt Sonja I. , Boeing Heiner , Bueno-de-Mesquita H. Bas , Crawford E. David , Diver W. Ryan , Gaziano J. Michael , Giles Graham G. , Giovannucci Edward , Gonzalez Carlos A. , Henderson Brian , Hunter David J. , Johansson Mattias , Kolonel Laurence N. , Ma Jing , Le Marchand Loïc , Pala Valeria , Stampfer Meir , Stram Daniel O. , Thun Michael J. , Tjonneland Anne , Trichopoulos Dimitrios , Virtamo Jarmo , Weinstein Stephanie J. , Willett Walter C. , Yeager Meredith , Hayes Richard B. , Severi Gianluca , Haiman Christopher A. , Chanock Stephen J. , Kraft Peter
Published: April 2023

Abstract
Background: One of the goals of personalized medicine is to generate individual risk profiles that could identify individuals in the population that exhibit high risk. The discovery of more than two-dozen independent single-nucleotide polymorphism markers in prostate cancer has raised the possibility for such risk stratification. In this study, we evaluated the discriminative and predictive ability for prostate cancer risk models incorporating 25 common prostate cancer genetic markers, family history of prostate cancer, and age.

Methods: We fit a series of risk models and estimated their performance in 7,509 prostate cancer cases and 7,652 controls within the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). We also calculated absolute risks based on SEER incidence data.

Results: The best risk model (C-statistic = 0.642) included individual genetic markers and family history of prostate cancer. We observed a decreasing trend in discriminative ability with advancing age (P = 0.009), with highest accuracy in men younger than 60 years (C-statistic = 0.679). The absolute ten-year risk for 50-year-old men with a family history ranged from 1.6% (10th percentile of genetic risk) to 6.7% (90th percentile of genetic risk). For men without family history, the risk ranged from 0.8% (10th percentile) to 3.4% (90th percentile).

Conclusions: Our results indicate that incorporating genetic information and family history in prostate cancer risk models can be particularly useful for identifying younger men that might benefit from prostate-specific antigen screening.

Impact: Although adding genetic risk markers improves model performance, the clinical utility of these genetic risk models is limited. Cancer Epidemiol Biomarkers Prev; 21(3); 437–44. ©2012 AACR.
Data from Total and Free Circulating Vitamin D and Vitamin D–Binding Protein in Relation to Colorectal Cancer Risk in a Prospective Study of African Americans
Authors: Andersen Shaneda Warren , Shu Xiao-Ou , Cai Qiuyin , Khankari Nikhil K. , Steinwandel Mark D. , Jurutka Peter W. , Blot William J. , Zheng Wei
Published: April 2023

Abstract
Background: Previous studies rarely evaluated the associations between vitamin D–binding protein and free vitamin D with colorectal cancer risk. We assessed these biomarkers and total 25-hydroxyvitamin D in relation to colorectal cancer risk in a sample of African Americans.

Methods: Cases comprised 224 African American participants of the Southern Community Cohort Study diagnosed with incident colorectal cancer. Controls (N = 440) were selected through incidence density sampling and matched to cases on age, sex, and race. Conditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for associations between biomarker levels and colorectal cancer risk.

Results: Vitamin D was inversely associated with colorectal cancer risk where the OR per-SD increase in total and free 25-hydroxyvitamin D were 0.82 (95% CI, 0.66–1.02) and 0.82 (95% CI, 0.66–1.01), respectively. Associations were most apparent among cases diagnosed >3 years after blood draw: ORs for the highest tertile versus the lowest were 0.69 (95% CI, 0.21–0.93) for total 25-hydroxyvitamin D and 0.71 (95% CI, 0.53–0.97) for free 25-hydroxyvitamin D. Inverse associations were seen in strata defined by sex, BMI, and anatomic site, although not all findings were statistically significant. Vitamin D–binding protein was not associated with colorectal cancer risk.

Conclusions: Our findings suggest that total and free 25-hydroxyvitamin D may be inversely associated with colorectal cancer risk among African Americans.

Impact: These findings highlight a potential role for vitamin D in colorectal cancer prevention in African Americans. Cancer Epidemiol Biomarkers Prev; 26(8); 1242–7. ©2017 AACR.
Data from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History
Authors: Weisenberger Daniel J. , Levine A. Joan , Long Tiffany I. , Buchanan Daniel D. , Walters Rhiannon , Clendenning Mark , Rosty Christophe , Joshi Amit D. , Stern Mariana C. , Le Marchand Loic , Lindor Noralane M. , Daftary Darshana , Gallinger Steven , Selander Teresa , Bapat Bharati , Newcomb Polly A. , Campbell Peter T. , Casey Graham , Ahnen Dennis J. , Baron John A. , Haile Robert W. , Hopper John L. , Young Joanne P. , Laird Peter W. , Siegmund Kimberly D.
Published: April 2023

Abstract
Background: The CpG island methylator phenotype (CIMP) represents a subset of colorectal cancers characterized by widespread aberrant DNA hypermethylation at select CpG islands. The risk factors and environmental exposures contributing to etiologic heterogeneity between CIMP and non-CIMP tumors are not known.

Methods: We measured the CIMP status of 3,119 primary population-based colorectal cancer tumors from the multinational Colon Cancer Family Registry. Etiologic heterogeneity was assessed by a case–case study comparing risk factor frequency of colorectal cancer cases with CIMP and non-CIMP tumors using logistic regression to estimate the case–case odds ratio (ccOR).

Results: We found associations between tumor CIMP status and MSI-H (ccOR = 7.6), BRAF V600E mutation (ccOR = 59.8), proximal tumor site (ccOR = 9; all P < 0.0001), female sex [ccOR = 1.8; 95% confidence interval (CI), 1.5–2.1], older age (ccOR = 4.0 comparing over 70 years vs. under 50; 95% CI, 3.0–5.5), and family history of CRC (ccOR = 0.6; 95% CI, 0.5–0.7). While use of NSAIDs varied by tumor CIMP status for both males and females (P = 0.0001 and P = 0.02, respectively), use of multivitamin or calcium supplements did not. Only for female colorectal cancer was CIMP status associated with increased pack-years of smoking (Ptrend < 0.001) and body mass index (BMI; Ptrend = 0.03).

Conclusions: The frequency of several colorectal cancer risk factors varied by CIMP status, and the associations of smoking and obesity with tumor subtype were evident only for females.

Impact: Differences in the associations of a unique DNA methylation–based subgroup of colorectal cancer with important lifestyle and environmental exposures increase understanding of the molecular pathologic epidemiology of this heavily methylated subset of colorectal cancer. Cancer Epidemiol Biomarkers Prev; 24(3); 512–9. ©2015 AACR.
Data from Contextual Impact of Neighborhood Obesogenic Factors on Postmenopausal Breast Cancer: The Multiethnic Cohort
Authors: Conroy Shannon M. , Clarke Christina A. , Yang Juan , Shariff-Marco Salma , Shvetsov Yurii B. , Park Song-Yi , Albright Cheryl L. , Hertz Andrew , Monroe Kristine R. , Kolonel Laurence N. , Marchand Loïc Le , Wilkens Lynne R. , Gomez Scarlett Lin , Cheng Iona
Published: April 2023

Abstract
Background: While obesity is well-understood to increase breast cancer risk, the role of the neighborhood obesogenic environment, encompassing social and built environment attributes that influence body size, is poorly understood.

Methods: Using principal components factor analysis, five composite factors [neighborhood socioeconomic status (nSES), urban, mixed-land development, unhealthy food environment, parks] on the basis of geospatial data were developed to characterize the obesogenic environment for 48,247 postmenopausal women in the Multiethnic Cohort, residing predominately in Los Angeles County. We used Cox proportional hazards regression to examine the association between neighborhood obesogenic factors and breast cancer risk (n = 2,341 cases after 17 years of follow-up), adjusting for body mass index (BMI), weight gain since age 21, education, established risk factors, other neighborhood factors, and clustering by block group.

Results: Lower nSES was associated with lower breast cancer risk [quintile 1 vs. 5: HR, 0.79; 95% confidence interval (CI), 0.66–0.95], with a more pronounced association observed in Latinos (quintile 1 vs. 5: HR, 0.60; 95% CI, 0.43–0.85). More urban environments were associated with lower breast cancer risk in Japanese Americans (quintile 5 vs. 1: HR, 0.49; 95% CI, 0.26–0.90), and lower mixed-land development was associated with higher breast cancer risk in Latinos (quintile 1 vs. 5: HR, 1.46; 95% CI, 1.10–1.93).

Conclusions: Obesogenic neighborhood environment factors, especially nSES, urbanicity, and mixed-land development, were differentially and independently associated with breast cancer risk in this multiethnic population.

Impact: These findings highlight the need for additional studies of the driving contextual aspects of nSES that influence breast cancer risk. Cancer Epidemiol Biomarkers Prev; 26(4); 480–9. ©2017 AACR.

See all the articles in this CEBP Focus section, “Geospatial Approaches to Cancer Control and Population Sciences.”
Data from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus
Authors: Critchley-Thorne Rebecca J. , Duits Lucas C. , Prichard Jeffrey W. , Davison Jon M. , Jobe Blair A. , Campbell Bruce B. , Zhang Yi , Repa Kathleen A. , Reese Lia M. , Li Jinhong , Diehl David L. , Jhala Nirag C. , Ginsberg Gregory , DeMarshall Maureen , Foxwell Tyler , Zaidi Ali H. , Lansing Taylor D. , Rustgi Anil K. , Bergman Jacques J.G.H.M. , Falk Gary W.
Published: April 2023

Abstract
Background: Better methods are needed to predict risk of progression for Barrett's esophagus. We aimed to determine whether a tissue systems pathology approach could predict progression in patients with nondysplastic Barrett's esophagus, indefinite for dysplasia, or low-grade dysplasia.

Methods: We performed a nested case–control study to develop and validate a test that predicts progression of Barrett's esophagus to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), based upon quantification of epithelial and stromal variables in baseline biopsies. Data were collected from Barrett's esophagus patients at four institutions. Patients who progressed to HGD or EAC in ≥1 year (n = 79) were matched with patients who did not progress (n = 287). Biopsies were assigned randomly to training or validation sets. Immunofluorescence analyses were performed for 14 biomarkers and quantitative biomarker and morphometric features were analyzed. Prognostic features were selected in the training set and combined into classifiers. The top-performing classifier was assessed in the validation set.

Results: A 3-tier, 15-feature classifier was selected in the training set and tested in the validation set. The classifier stratified patients into low-, intermediate-, and high-risk classes [HR, 9.42; 95% confidence interval, 4.6–19.24 (high-risk vs. low-risk); P < 0.0001]. It also provided independent prognostic information that outperformed predictions based on pathology analysis, segment length, age, sex, or p53 overexpression.

Conclusion: We developed a tissue systems pathology test that better predicts risk of progression in Barrett's esophagus than clinicopathologic variables.

Impact: The test has the potential to improve upon histologic analysis as an objective method to risk stratify Barrett's esophagus patients. Cancer Epidemiol Biomarkers Prev; 25(6); 958–68. ©2016 AACR.
Data from Genome-wide Association Study of Prostate Cancer Mortality
Authors: Penney Kathryn L. , Pyne Saumyadipta , Schumacher Fredrick R. , Sinnott Jennifer A. , Mucci Lorelei A. , Kraft Peter L. , Ma Jing , Oh William K. , Kurth Tobias , Kantoff Philip W. , Giovannucci Edward L. , Stampfer Meir J. , Hunter David J. , Freedman Matthew L.
Published: April 2023

Abstract
Background: A pressing clinical issue in prostate cancer is to distinguish which men will have an indolent or aggressive course of disease. Clinical variables such as Gleason grade and stage are useful predictors of lethal cancer; however, the low predictive values of the common Gleason scores, changes in grading over time, and earlier diagnosis of patients due to screening limits their clinical utility. Identifying genetic variants associated with lethal prostate cancer could inform clinical decision making.

Methods: We conducted a genome-wide association study, comparing lethal prostate cancer cases to cases surviving at least 10 years beyond their initial diagnosis. Genotyping was done with the Affymetrix 5.0 chip [∼500,000 single nucleotide polymorphisms (SNP) and 1,483 copy number variants (CNV)] on DNA from participants in the Physicians' Health Study and Health Professionals Follow-up Study (196 lethal cases, 368 long-term survivors). After excluding SNPs and individuals based on quality control criteria, logistic regression assuming an additive model was done using the PLINK software.

Results: No SNP reached genome-wide significance (P ≤ 1 × 10−7); however, three independent SNPs had P < 1 × 10−5. One top-ranked SNP replicated (P = 0.05) in an independent follow-up study. Although no CNV had genome-wide significance, 14 CNVs showed nominal association with prostate cancer mortality (P < 0.05).

Conclusions: No variants were significantly associated at a genome-wide level with prostate cancer mortality. Common genetic determinants of lethal prostate cancer are likely to have odds ratios <2.0.

Impact: Genetic markers identified could provide biological insight to improve therapy for men with potentially fatal cancer. Larger studies are necessary to detect the genetic causes of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev; 19(11); 2869–76. ©2010 AACR.
Data from Genetic Variants of Nucleotide Excision Repair Genes Are Associated with DNA Damage in Coke Oven Workers
Authors: Wang Fang , He Yuefeng , Guo Huan , Li Jichao , Yang Yan , Wu Zhou , Zheng Hongyan , Wu Tangchun
Published: April 2023

Abstract
We explored the effects of single nucleotide polymorphisms (SNP) of nucleotide excision repair (NER) genes on DNA damage caused by exposure to carcinogenic polycyclic aromatic hydrocarbons (PAH) in 475 Chinese workers. We quantified urinary 1-hydroxypyrene using high-performance liquid chromatography, and the DNA damage level of lymphocytes was examined by the comet assay and represented as the Olive tail moment (OTM) value. We genotyped 38 tagSNPs in 10 NER genes. The SNP function was further investigated using luciferase reporter assay in three cell lines. Our results showed that two promoter SNPs, XPA rs1800975 and XPC rs3731055, were associated with lower OTM values (Ptrend = 0.01 and 0.02 respectively). However, another missense SNP rs2228001 in the XPC gene was positively associated with OTM value (Ptrend = 0.01). A stratified analysis found that the association between this SNP and DNA damage was only observed among subjects with higher PAH exposure levels but not among those with lower exposure levels (Pinteraction = 0.018). A dose-response association was found between the combined risk alleles of the above three genetic variants and increased DNA damage levels (Ptrend = 0.004). This association was more pronounced in subjects with higher PAH exposure than those with lower exposure levels (Pinteraction = 0.046). Our functional study indicated that XPA rs1800975G and XPC rs3731055A alleles had a higher luciferase expression than their corresponding SNP alleles (P < 0.05). These results suggested that genetic variations in key NER genes, especially in XPA and XPC genes, may modulate DNA damage levels when exposed to PAHs. Cancer Epidemiol Biomakers Prev; 19(1); 211–8
Supplementary Figures 1-3 from Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Authors: Sun Jessica D. , Liu Qian , Wang Jingli , Ahluwalia Dharmendra , Ferraro Damien , Wang Yan , Duan Jian-Xin , Ammons W. Steve , Curd John G. , Matteucci Mark D. , Hart Charles P.
Published: April 2023

PDF file - 2.7MB
Supplementary Table 3 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Authors: Grassilli Emanuela , Narloch Robert , Federzoni Elena , Ianzano Leonarda , Pisano Fabio , Giovannoni Roberto , Romano Gabriele , Masiero Laura , Leone Biagio Eugenio , Bonin Serena , Donada Marisa , Stanta Giorgio , Helin Kristian , Lavitrano Marialuisa
Published: April 2023

Supplementary Table 3 - PDF file 74K, Correlation between activated GSK3B and patients outcome
Supplementary Tables S1 and S2 from Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2
Authors: Varsano Tal , Lau Eric , Feng Yongmei , Garrido Marine , Milan Loribelle , Heynen-Genel Susanne , Hassig Christian A. , Ronai Ze'ev A.
Published: April 2023

Supplementary Tables S1 and S2 - PDF file 100K, Supplementary Table S1. The top 20 upregulated genes in WM793 cells treated for 24 h with SBI-087702 as compared to DMSO-treated cells; Supplementary Table S2. The top 20 downregulated genes in WM793 cells treated for 24 h with SBI-0087702 as compared to DMSO-treated cells
Supplementary Methods Legends and References from Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2
Authors: Varsano Tal , Lau Eric , Feng Yongmei , Garrido Marine , Milan Loribelle , Heynen-Genel Susanne , Hassig Christian A. , Ronai Ze'ev A.
Published: April 2023

Supplementary Methods Legends and References - PDF file 163K, Supplementary Methods, Legends for Figures, and References
Supplementary Figure 4 from FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51
Authors: Zhang Nu , Wu Xinjian , Yang Lixuan , Xiao Feizhe , Zhang Heng , Zhou Aidong , Huang Zhengsong , Huang Suyun
Published: April 2023

PDF file - 104K, Supplementary Fig. 4. FoxM1 mediates the resistant effect to TMZ in recurrent GBM cells through Rad51
Data Supplement from Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival
Authors: Zhong Yi , Naito Yoshiki , Cope Leslie , Naranjo-Suarez Salvador , Saunders Tyler , Hong Seung-Mo , Goggins Michael G. , Herman Joseph M. , Wolfgang Christopher L. , Iacobuzio-Donahue Christine A.
Published: April 2023

Supplemental Figure 4. Stress Response Data
Supplementary Figure 6 from Targeted Therapy for BRAFV600E Malignant Astrocytoma
Authors: Nicolaides Theodore P. , Li Huifang , Solomon David A. , Hariono Sujatmi , Hashizume Rintaro , Barkovich Krister , Baker Suzanne J. , Paugh Barbara S. , Jones Chris , Forshew Tim , Hindley Guy F. , Hodgson J. Graeme , Kim Jung-Sik , Rowitch David H. , Weiss William A. , Waldman Todd A. , James C. David
Published: April 2023

PDF file - 185K
Supplementary Figure 3 from Targeted Therapy for BRAFV600E Malignant Astrocytoma
Authors: Nicolaides Theodore P. , Li Huifang , Solomon David A. , Hariono Sujatmi , Hashizume Rintaro , Barkovich Krister , Baker Suzanne J. , Paugh Barbara S. , Jones Chris , Forshew Tim , Hindley Guy F. , Hodgson J. Graeme , Kim Jung-Sik , Rowitch David H. , Weiss William A. , Waldman Todd A. , James C. David
Published: April 2023

PDF file - 261K
Supplementary Tables 1 - 2 from Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Authors: McCourt Clare , Maxwell Pamela , Mazzucchelli Roberta , Montironi Rodolfo , Scarpelli Marina , Salto-Tellez Manuel , O'Sullivan Joe M. , Longley Daniel B. , Waugh David J.J.
Published: April 2023

PDF file, 22KB, Description of pathological specimens (Table S1) and immunohistochemical detection of c-FLIP in prostate tissues (Table S2).
Supplementary Figure 4 from Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Authors: McCourt Clare , Maxwell Pamela , Mazzucchelli Roberta , Montironi Rodolfo , Scarpelli Marina , Salto-Tellez Manuel , O'Sullivan Joe M. , Longley Daniel B. , Waugh David J.J.
Published: April 2023

PDF file, 41KB, Effects of SAHA and bicalutamide in inducing apoptosis detected by Annexin-V labelling.
Supplementary Figure 1 from Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy
Authors: McCourt Clare , Maxwell Pamela , Mazzucchelli Roberta , Montironi Rodolfo , Scarpelli Marina , Salto-Tellez Manuel , O'Sullivan Joe M. , Longley Daniel B. , Waugh David J.J.
Published: April 2023

PDF file, 202KB, Silencing of c-FLIP induces spontaneous apoptosis in CaP cells.
Supplementary Table 1 from Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
Authors: Tang Patricia A. , Cohen Steven J. , Kollmannsberger Christian , Bjarnason Georg , Virik Kiran , MacKenzie Mary J. , Lourenco Lillian , Wang Lisa , Chen Alice , Moore Malcolm J.
Published: April 2023

PDF file - 34K, Relationship between the presence of grade 1 or greater hypertension and best response to aflibercept
Supplementary Figure Legend from Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer
Authors: Belkhiri Abbes , Zhu Shoumin , Chen Zheng , Soutto Mohammed , El-Rifai Wael
Published: April 2023

PDF file, 62KB.
Supplementary Figure 2 from Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies
Authors: Fischer Eliane , Chaitanya Krishna , Wüest Thomas , Wadle Andreas , Scott Andrew M. , van den Broek Maries , Schibli Roger , Bauer Stefan , Renner Christoph
Published: April 2023

PDF file - 54K, Recombinant expression of Fab fragments and antibodies
Supplementary Figure 6 from IL-17–Mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws
Authors: Zhang Qunzhou , Atsuta Ikiru , Liu Shiyu , Chen Chider , Shi Shihong , Shi Songtao , Le Anh D.
Published: April 2023

PDF file - 31K, Mice BMDMs were continuously cultured under M1 macrophage polarization condition (IFN-, 20ng/mL) in the presence or absence of murine IL-17 (10ng/mL) for different time periods, and the phosphorylated STAT-1 levels determined by Western blot as shown in Figure 6C were normalized to the corresponding expression level of total STAT-1., whereby the graphs show the relative densities of p-STAT-1.
Supplementary Figure 4 from IL-17–Mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws
Authors: Zhang Qunzhou , Atsuta Ikiru , Liu Shiyu , Chen Chider , Shi Shihong , Shi Songtao , Le Anh D.
Published: April 2023

PDF file - 444K, Representative microCT of BRONJ-like lesions and X-radiographs of normal healing of tibia in BgXID (III) nu/nu mice.
Supplementary Figure 1 from Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model
Authors: van der Bilt Arne R.M. , van Scheltinga Anton G.T. Terwisscha , Timmer-Bosscha Hetty , Schröder Carolien P. , Pot Linda , Kosterink Jos G.W. , van der Zee Ate G.J. , Lub-de Hooge Marjolijn N. , de Jong Steven , de Vries Elisabeth G.E. , Reyners Anna K.L.
Published: April 2023

PDF file - 20K, Schematic representation of the study design
Supplementary Figure 1 from Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression
Authors: Schwarzenbach Heidi , Eichelser Corinna , Kropidlowski Jolanthe , Janni Wolfgang , Rack Brigitte , Pantel Klaus
Published: April 2023

PDF file, 35K, Supplementary Figure S1. Kaplan-Meier analyses of primary breast cancer patients with positive and negative estrogen receptor (ER) status. Top curve shows patients with positive ER status, and bottom curve patients with negative ER status (see also Table 1).
Supplementary Figure 2 from L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
Authors: Mehta Neelima R. , Wurz Gregory T. , Burich Rebekah A. , Greenberg Brittany E. , Griffey Stephen , Gutierrez Audrey , Bell Katie E. , McCall Jamie L. , Wolf Michael , DeGregorio Michael
Published: April 2023

PDF file - 87K, Kaplan-Meier survival curves comparing the vaccine alone treatment group with the tamoxifen (A), letrozole (B), and estradiol (C) plus vaccine combination treatment groups are shown (N=7, all groups)
Supplementary Methods from Integrin αvβ3-Targeted IRDye 800CW Near-Infrared Imaging of Glioblastoma
Authors: Huang Ruimin , Vider Jelena , Kovar Joy L. , Olive D. Michael , Mellinghoff Ingo K. , Mayer-Kuckuk Philipp , Kircher Moritz F. , Blasberg Ronald G.
Published: April 2023

PDF file, 80K.
Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid–Mediated Differentiation in Neuroblastoma
Authors: Shah Nilay , Wang Jianjun , Selich-Anderson Julia , Graham Garrett , Siddiqui Hasan , Li Xin , Khan Javed , Toretsky Jeffrey
Published: April 2023

Supplementary Methods, including MYCN status of cell lines used, specific Western blot methods, antibodies used and at which concentrations, and primers used in RT-qPCR.
Data Supplement from PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid–Mediated Differentiation in Neuroblastoma
Authors: Shah Nilay , Wang Jianjun , Selich-Anderson Julia , Graham Garrett , Siddiqui Hasan , Li Xin , Khan Javed , Toretsky Jeffrey
Published: April 2023

Supplementary Figure 2. Morphologic and protein expression (by immunofluorescence) effects of PBX1 expression in neuroblastoma cell lines
Supplementary Figure 3 from Comparison of Statistical Analysis Plans in Randomize-All Phase III Trials with a Predictive Biomarker
Authors: Matsui Shigeyuki , Choai Yuki , Nonaka Takahiro
Published: April 2023

PDF file - 63KB, P overall, P subset, and P success, for various numbers of events, E, under a quantitative interaction (HR+, HR−) = (0.5, 0.8).
Supplementary Figure 2 from Characteristics of Lung Cancers Harboring NRAS Mutations
Authors: Ohashi Kadoaki , Sequist Lecia V. , Arcila Maria E. , Lovly Christine M. , Chen Xi , Rudin Charles M. , Moran Teresa , Camidge David Ross , Vnencak-Jones Cindy L. , Berry Lynne , Pan Yumei , Sasaki Hidefumi , Engelman Jeffrey A. , Garon Edward B. , Dubinett Steven M. , Franklin Wilbur A. , Riely Gregory J. , Sos Martin L. , Kris Mark G. , Dias-Santagata Dora , Ladanyi Marc , Bunn Paul A. , Pao William
Published: April 2023

PDF file - 70K, Figure S2. Effect of a MEK inhibitor against HCC15 cells in combination with either a MET or IGF-1R inhibitor. A. The combination of SGX-523 and trametinib did not inhibit cell growth in HCC15 cells. B. The combination of linsitiniband trametinib showed a greater effect than either drug alone. We used linsitinib because we previously reported that HCC15 cells harbor high levels of IGF-1R (36).
Supplementary Figure 2 from A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer
Authors: Marin-Muller Christian , Li Dali , Bharadwaj Uddalak , Li Min , Chen Changyi , Hodges Sally E. , Fisher William E. , Mo Qianxing , Hung Mien-Chie , Yao Qizhi
Published: April 2023

Supplementary Figure 2 - PDF file 207K, PBX-1 and VCP are predicted targets for miR-198
Supplementary Figure 3 from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Authors: Kachala Stefan S. , Bograd Adam J. , Villena-Vargas Jonathan , Suzuki Kei , Servais Elliot L. , Kadota Kyuichi , Chou Joanne , Sima Camelia S. , Vertes Eva , Rusch Valerie W. , Travis William D. , Sadelain Michel , Adusumilli Prasad S.
Published: April 2023

PDF file - 367K, Supplementary Fig. S3. Mediastinal lymph node metastasis and Ki-67 expression in an orthotopic model of adenocarcinoma (ADC) with mesothelin (MSLN) overexpression.
Supplementary Figure 1 from Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Authors: Patankar Nilesh A. , Pritchard Julia , van Grinsven Mariska , Osooly Maryam , Bally Marcel B.
Published: April 2023

PDF file - 66 KB, Kaplan-Meier survival plot of Ncr-Nude mice bearing intraperitoneally grown ES-2 clear cell carcinoma xenografts after i.v treatment (q7d x 3) with free topotecan, Topophore C and Doxil either as single agents or in combination as shown shown. Data points represent mean � SD, (n � 6).
Supplementary Methods from Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth
Authors: Yepuru Muralimohan , Wu Zhongzhi , Kulkarni Anand , Yin Feng , Barrett Christina M. , Kim Juhyun , Steiner Mitchell S. , Miller Duane D. , Dalton James T. , Narayanan Ramesh
Published: April 2023

Supplementary Methods - PDF file 62K, Additional methods to support the manuscript 1. Cloning and protein purification 2. AKR1C3 enzyme activity and thin layer chromatography (TLC)
Supplementary Figure 1 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
Authors: Blatt Katharina , Herrmann Harald , Hoermann Gregor , Willmann Michael , Cerny-Reiterer Sabine , Sadovnik Irina , Herndlhofer Susanne , Streubel Berthold , Rabitsch Werner , Sperr Wolfgang R. , Mayerhofer Matthias , Rülicke Thomas , Valent Peter
Published: April 2023

PDF file - 162K, Supplementary Figure S1A: Expression of CD52 on CD34+/CD38+ cells in MDS and AML Supplementary Figure S1B: Expression of CD52 on CD34+/CD38+ cells in MDS, AML and control samples.
Supplementary Figure 2 from In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Authors: Schalper Kurt A. , Velcheti Vamsidhar , Carvajal Daniel , Wimberly Hallie , Brown Jason , Pusztai Lajos , Rimm David L.
Published: April 2023

PDF file - 978K, Figure S2, Reproducibility of in situ mRNA measurements.
Supplementary Figure 5 from Downregulation of miR-138 Sustains NF-κB Activation and Promotes Lipid Raft Formation in Esophageal Squamous Cell Carcinoma
Authors: Gong Hui , Song Libing , Lin Chuyong , Liu Aibin , Lin Xi , Wu Jueheng , Li Mengfeng , Li Jun
Published: April 2023

PDF file - 88 KB, Blockade of the NF-�B pathway via overexpressing I�B�-mut inhibits miR-138 downregulation-induced ESCC progression.
Supplementary Figure 4 from Downregulation of miR-138 Sustains NF-κB Activation and Promotes Lipid Raft Formation in Esophageal Squamous Cell Carcinoma
Authors: Gong Hui , Song Libing , Lin Chuyong , Liu Aibin , Lin Xi , Wu Jueheng , Li Mengfeng , Li Jun
Published: April 2023

PDF file - 39 KB, Silencing miR-138 sustains NF-�B activity.
Supplementary Figure 3 from Downregulation of miR-138 Sustains NF-κB Activation and Promotes Lipid Raft Formation in Esophageal Squamous Cell Carcinoma
Authors: Gong Hui , Song Libing , Lin Chuyong , Liu Aibin , Lin Xi , Wu Jueheng , Li Mengfeng , Li Jun
Published: April 2023

PDF file - 231 KB, Overexpression of miR-138 inhibits the malignant properties of ESCC cells.
Supplementary Figure Legend from CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Authors: Ye Qunrui , Song De-Gang , Poussin Mathilde , Yamamoto Tori , Best Andrew , Li Chunsheng , Coukos George , Powell Daniel J.
Published: April 2023

Supplementary Figure Legend - PDF file 61K, Supplementary figure legend
Supporting Information from The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression
Authors: Salvador Marion A. , Wicinski Julien , Cabaud Olivier , Toiron Yves , Finetti Pascal , Josselin Emmanuelle , Lelièvre Hélène , Kraus-Berthier Laurence , Depil Stéphane , Bertucci François , Collette Yves , Birnbaum Daniel , Charafe-Jauffret Emmanuelle , Ginestier Christophe
Published: April 2023

PDF file 68K, Supplementary materials and methods
Supplementary Methods from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Authors: Coiffier Bertrand , Li Weimin , Henitz Erin D. , Karkera Jayaprakash D. , Favis Reyna , Gaffney Dana , Shapiro Alice , Theocharous Panteli , Elsayed Yusri A. , van de Velde Helgi , Schaffer Michael E. , Osmanov Evgenii A. , Hong Xiaonan , Scheliga Adriana , Mayer Jiri , Offner Fritz , Rule Simon , Teixeira Adriana , Romejko-Jarosinska Joanna , de Vos Sven , Crump Michael , Shpilberg Ofer , Zinzani Pier Luigi , Cakana Andrew , Esseltine Dixie-Lee , Mulligan George , Ricci Deborah
Published: April 2023

Supplementary Methods PDF file 64K, TaqMan SNP Genoytping Assays and Ligation-based Multiplexed Genotyping Assays
Fig. S5 from The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer
Authors: Heckmann Doreen , Maier Patrick , Laufs Stephanie , Li Li , Sleeman Jonathan P. , Trunk Marcus J. , Leupold Jörg H. , Wenz Frederik , Zeller W. Jens , Fruehauf Stefan , Allgayer Heike
Published: April 2023

PDF file 95K, S5: Correlation analysis of expression of AXL, IGFBP7 and AKR1C3 in tumor tissue with various clinicopathological features
Figure S1 from Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer
Authors: Schuler Patrick J. , Harasymczuk Malgorzata , Schilling Bastian , Saze Zenichiro , Strauss Laura , Lang Stephan , Johnson Jonas T. , Whiteside Theresa L.
Published: April 2023

PDF file 54K, Box plots show percentages of CD19+ B cells in the peripheral circulation of HNSCC patients who were untreated (AD) or had no evident disease at the time of phlebotomy after receiving therapy with surgery only (SRG) or adjuvant chemoradiotherapy (CRT). (*p = 0.05)
Supplementary Table 4 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
Authors: Bartlett Edmund K. , Fetsch Patricia A. , Filie Armando C. , Abati Andrea , Steinberg Seth M. , Wunderlich John R. , White Donald E. , Stephens Daniel J. , Marincola Francesco M. , Rosenberg Steven A. , Kammula Udai S.
Published: April 2023

PDF file - 51K, Pairwise comparison of antigen expression by individual anatomic site cluster. Shown are p value results of Cochran-Armitage test for trend. p <0.005 considered significant (bold, underlined), p <0.05-0.005 considered a trend (bold).
Supplementary Fig. 4 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Authors: Phillips Gail D. Lewis , Fields Carter T. , Li Guangmin , Dowbenko Donald , Schaefer Gabriele , Miller Kathy , Andre Fabrice , Burris Howard A. , Albain Kathy S. , Harbeck Nadia , Dieras Veronique , Crivellari Diana , Fang Liang , Guardino Ellie , Olsen Steven R. , Crocker Lisa M. , Sliwkowski Mark X.
Published: April 2023

PDF file 158K, NRG protects BT-474, but not KPL-4, breast cancer cells from cytotoxicity induced by anti-mitotic agents DM1, docetaxel and vinorelbine